The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test
{{output}}
The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway is frequently activated in many cancers, including prostate cancer where this is often following loss of phosphatase and tensin homolog (PTEN). The CAPItello-281 trial is the first phase III t... ...
